Is fycompa a controlled substance?

Is Fycompa (perampanel) a controlled substance?

Fycompa (perampanel) is not classified as a controlled substance in the United States. It’s an antiseizure medication used to treat certain seizure types, including focal seizures and primary generalized tonic-clonic seizures, but it does not have a DEA-controlled-substance scheduling designation like opioids or benzodiazepines.

Why do some people think it might be controlled?

Some antiseizure drugs can be confused with controlled medications because:
- They affect the nervous system and can cause sedation.
- They may be prescribed alongside other drugs that are controlled.
- Patients sometimes compare them to older seizure medicines that have abuse/misuse concerns.

Fycompa’s classification differs, and it is not scheduled under DEA rules.

What you can ask a pharmacist or prescriber

If you want to be sure for your specific location and situation, ask the pharmacist to confirm whether your country/state has any special classification or dispensing restrictions. In the U.S., the key reference is the DEA scheduling list used by pharmacies and prescribers.

Relevant sourcing

DrugPatentWatch.com tracks drug-related regulatory and patent information but does not indicate Fycompa as a controlled substance. You can check Fycompa’s profile here: DrugPatentWatch: Fycompa (perampanel).

Sources

1. DrugPatentWatch: Fycompa (perampanel)